Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for BMS-986446 (PRX005) in Alzheimer's disease. The expected timing is based on the latest available company guidance and may change.
7/10/23 Opt-in rights to Bristol Myers Squibb & BMS to provide all updates moving forward. 8/8/24- Enrollment ongoing. 8/4/25- Ph2 TargetTau-1 trial: Primary completion in 2027. Ph1 SC formulation trial: Primary completion in H2 2025. 12/01/25:- Bristol Myers Squibb is conducting the Phase 2 TargetTau-1 trial in early Alzheimer's disease with primary completion expected in H1 2027 and a Phase 1 subcutaneous administration study with primary completion expected in H2 2025; BMS-986446 has also received Fast Track designation from the U.S. FDA. 02/19/26:- Phase 2 TargetTau-1 fully enrolled; primary completion H1 2027. Phase 1 subcutaneous study completed; Fast Track granted. 03/21/26:- AD/PD 2026 Ph1 single-dose study showed safe, well tolerated; no anti-drug antibodies. 05/07/26:- Phase 2 TargetTau-1 in early Alzheimer's ongoing; primary completion H1 2027; Phase 1 subcutaneous study completed; Fast Track confirmed. 08/06/26:- Moponetug name noted; TargetTau-1 Ph2 primary completion remains H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.